Thursday, November 7, 2013
This week in techniques
Publication and contact
Fibrillin 1 (Fbn1)-mutant mouse models
of systemic scleroderma
Mice harboring mutations in
the integrin-binding domain of Fbn1 could help model systemic scleroderma.
The mice exhibited multiple disease features seen in patients with systemic
scleroderma or patient fibroblasts, including high levels of collagen,
activated integrin b3
(GPIIIa; CD61) in the skin and high
levels of antinuclear antibodies in circulation. Compared with control IgG,
an integrin b1
decreased CD61 activity and collagen expression in patient fibroblasts, skin
fibrosis and levels of circulating antinuclear antibodies in the mice. Future
studies could include using the models to compare the efficacy and safety of
CD29-activating and CD61-inhibiting antibodies.
Mitsubishi Tanabe Pharma Corp.'s
Venoglobulin IH (GB-0998), a liquid human
IgG preparation derived from donated plasma, is in Phase III testing to treat
arGentis Pharmaceuticals LLC's
ARG201, a solubilized type
I native bovine collagen, is in Phase II testing to treat systemic
Published online Nov. 7, 2013
Patent and licensing status
Gerber, E.E. et al.
Nature; published online Oct. 9, 2013;
Contact: Harry C. Dietz, The Johns Hopkins University School
of Medicine, Baltimore, Md.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]